Alpha Cognition (NASDAQ:ACOG) Upgraded by Raymond James to “Moderate Buy” Rating

Raymond James upgraded shares of Alpha Cognition (NASDAQ:ACOG) to a moderate buy rating in a report released on Tuesday,Zacks.com reports.

Separately, HC Wainwright started coverage on Alpha Cognition in a research report on Tuesday, March 18th. They issued a “buy” rating and a $20.00 target price on the stock.

Alpha Cognition Trading Up 0.7 %

Alpha Cognition stock opened at $5.52 on Tuesday. The company has a fifty day simple moving average of $5.87. Alpha Cognition has a 1-year low of $4.66 and a 1-year high of $7.00. The company has a market capitalization of $88.43 million, a P/E ratio of -2.16 and a beta of 2.50.

Institutional Trading of Alpha Cognition

A number of hedge funds have recently made changes to their positions in ACOG. National Bank of Canada FI bought a new stake in Alpha Cognition in the 4th quarter valued at $69,000. Manatuck Hill Partners LLC acquired a new position in shares of Alpha Cognition in the fourth quarter valued at $395,000. Tudor Investment Corp ET AL bought a new position in shares of Alpha Cognition in the fourth quarter valued at about $412,000. MYDA Advisors LLC acquired a new stake in shares of Alpha Cognition during the 4th quarter worth about $589,000. Finally, Bleichroeder LP bought a new stake in shares of Alpha Cognition during the 4th quarter worth about $1,024,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.